Page last updated: 2024-09-05

varenicline and Behavior Disorders

varenicline has been researched along with Behavior Disorders in 60 studies

Research

Studies (60)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	12 (20.00)	29.6817
2010's	44 (73.33)	24.3611
2020's	4 (6.67)	2.80

Authors

Authors	Studies
Kalin, NH	1
Berk, M; Billeci, M; Carvalho, AF; Castle, DJ; de Bartolomeis, A; De Prisco, M; Fornaro, M; Iasevoli, F; Mondin, AM; Selby, P	1
Cunningham, F; Desai, RJ; Good, CB; Good, MM; Henriksen, A; Hernandez, I; San-Juan-Rodriguez, A	1
Bassett, K; Carney, G; Dormuth, CR; Maclure, M; Taylor, S	1
Kotz, D; Sheikh, A; Simpson, CR; van Schayck, OCP; Viechtbauer, W; West, R	1
Brabyn, S; Cook, L; Gilbody, S; Peckham, E; Tew, G	1
Campitelli, MA; Gershon, AS; Hawken, S; Kurdyak, P; Selby, P; Sproule, BA; Victor, C	1
Geyer, MA; Phillips, AG; Robbins, TW	1
Bullen, C; Galea-Singer, S; Kurdziel, T; Laking, G; Newcombe, D; Parag, V; Verbiest, M; Walker, N	1
Clark, A; Clyde, M; Els, C; Fu, A; Pipe, A; Reid, R; Tulloch, H	1
Anthenelli, RM; Benowitz, NL; Evins, AE; Gaffney, M; Krishen, A; Lawrence, D; McRae, T; Russ, C; St Aubin, L; West, R	1
Davies, NM; Itani, T; Jones, T; Martin, RM; Munafò, MR; Rai, D; Taylor, AE; Taylor, GMJ; Thomas, KH; Windmeijer, F	1
Hviid, A; Pasternak, B; Svanström, H	1
Buggy, Y; Cornelius, V; Fogg, C; Kasliwal, R; Layton, D; Shakir, SA	1
Gibbons, RD; Mann, JJ	1
Aitken, D; Clyde, M; Corran, B; Els, C; Pipe, A; Reid, RD; Tulloch, H	1
Rausch, R	1
Gunnell, D; Higgins, JP; Knipe, DW; Martin, RM; Thomas, KH	1
Harrison-Woolrych, M	1
Fazel, S; Gumpert, CH; Lichtenstein, P; Molero, Y; Zetterqvist, J	1
Borse, MS; Brown, JD; Li, C; Shewale, AR	1
Akerman, S; Bartels, S; Brunette, MF; Dzebisashvili, N; Ferron, JC; Xie, H	1
Annamalai, A; O'Malley, SS; Singh, N	1
Kotz, D; Sheikh, A; Simpson, C; van Schayck, OC; Viechtbauer, W; West, R	3
Miller, ME; Tidey, JW	1
Leone, FT; Schnoll, R	1
Eden Evins, A; McNeill, A; Roberts, E; Robson, D	1
Burden, AM; Nielen, JT	1
Odeyale, F; Udo, I	1
Davies, NM; Martin, RM; Munafò, MR; Taylor, AE; Taylor, G; Thomas, KH	1
Aspinall, SL; Cunningham, FE; Dong, D; Good, CB; Graham, DJ; Hur, K; McCarren, M; Miller, DR; Mosholder, AD; Wei, X; Zhang, R	1
Anand, A; Fidler, L; Stanbrook, M	1
Brabyn, S; Gilbody, S; Parrott, S; Peckham, E; Wu, Q	1
Achtyes, ED; Cather, C; Evins, AE; Hoeppner, SS; Pachas, GN; Pratt, S; Thorndike, AN	1
Ballbè, M; Bruguera, E; Cano, M; Fernández, E; Fernández, T; Nieva, G; Raich, A	1
Anthenelli, RM; Ascher, J; Benowitz, NL; Evins, AE; Krishen, A; Lawrence, D; McRae, T; Russ, C; St Aubin, L; West, R	1
Nadeem, SS; Pirmoradi, P; Roshan, S	1
Boyd, JW; Lasser, KE	1
Tavares, AR	1
Balvanz, TM; Magallon, HE; Mambourg, SE; Pham, RH; Purvis, TL	1
Dupont, P; Gillet, C; Guerin, M; Guillaumin, C; Kalamarides, S; Larinier, E; Meignan, C; Moreau, A; Perriot, J	1
Cantrell, FL; Clark, AK; Clark, RF; Kreshak, AA; Ly, BT	1
Richins, C	1
Burke, MV; Ebbert, JO; Hays, J; Wyatt, KD; Zirakzadeh, A	1
Mambourg, SE; Nelson, LA; Purvis, TL	1
Davies, S; Flammer, M; Hughes, J; Russ, C; Tonstad, S	1
Catz, SL; Deprey, M; Jack, L; Javitz, H; McAfee, T; McClure, JB; Richards, J; Swan, GE; Zbikowski, SM	1
Furberg, CD; Glenmullen, J; Moore, TJ	1
Ashton, J; Harrison-Woolrych, M	1
Jones, DL; Rankin, KV	1
Coster, TS; Graham, DJ; Meyer, TE; Moeny, D; Mosholder, AD; Ouellet-Hellstrom, RP; Taylor, LG; Williams, JR; Xie, S	1
Ahmed, AI; Ali, AN; Burger, DM; Härmark, LV; Kramers, C; Verhoeven, WM	1
Arnsten, JH; Bernstein, SL; Nahvi, S; Richter, KP; Wu, B	1
Dervaux, A; Kanit, M; Laqueille, X	1
Milbrandt, A; Ratcliffe, M; Smith, R; Spirling, LI; Stapleton, JA; Sutherland, G; Watson, L	1
Kuehn, BM	1
Perno Goldie, M	1

Reviews

12 review(s) available for varenicline and Behavior Disorders

Article	Year
The prevalence, odds, predictors, and management of tobacco use disorder or nicotine dependence among people with severe mental illness: Systematic review and meta-analysis. Neuroscience and biobehavioral reviews, 2022, Volume: 132 Topics: Humans; Male; Mental Disorders; Prevalence; Smoking Cessation; Tobacco Use Disorder; Varenicline	2022
Smoking cessation in severe mental ill health: what works? an updated systematic review and meta-analysis. BMC psychiatry, 2017, 07-14, Volume: 17, Issue:1 Topics: Antidepressive Agents, Second-Generation; Bupropion; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Mental Disorders; Nicotinic Agonists; Smoking; Smoking Cessation; Varenicline	2017
Effective Use of Animal Models for Therapeutic Development in Psychiatric and Substance Use Disorders. Biological psychiatry, 2018, 06-01, Volume: 83, Issue:11 Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Depressive Disorder; Drug Discovery; Humans; Ketamine; Mental Disorders; Models, Animal; Nicotinic Agonists; Tobacco Use Disorder; Varenicline	2018
Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis. BMJ (Clinical research ed.), 2015, Mar-12, Volume: 350 Topics: Aggression; Benzazepines; Depression; Humans; Mental Disorders; Quinoxalines; Risk Factors; Sleep Wake Disorders; Suicide; Suicide, Attempted; Tobacco Use Cessation Devices; Varenicline	2015
Smoking Use and Cessation Among People with Serious Mental Illness. The Yale journal of biology and medicine, 2015, Volume: 88, Issue:3 Topics: Comorbidity; Connecticut; Female; Humans; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Prevalence; Retrospective Studies; Risk Factors; Smoking; Smoking Cessation; Smoking Prevention; Tobacco Use Cessation Devices; Treatment Outcome; Varenicline	2015
Smoking cessation and reduction in people with chronic mental illness. BMJ (Clinical research ed.), 2015, Sep-21, Volume: 351 Topics: Anxiety Disorders; Bipolar Disorder; Bupropion; Electronic Nicotine Delivery Systems; Humans; Mental Disorders; Mentally Ill Persons; Nicotinic Agonists; Prevalence; Reinforcement, Psychology; Schizophrenia; Smoking; Smoking Cessation; Stress Disorders, Post-Traumatic; Tobacco Use Cessation Devices; United Kingdom; United States; Varenicline	2015
Efficacy and tolerability of pharmacotherapy for smoking cessation in adults with serious mental illness: a systematic review and network meta-analysis. Addiction (Abingdon, England), 2016, Volume: 111, Issue:4 Topics: Bupropion; Humans; Mental Disorders; Nicotinic Agonists; Smoking Cessation; Tobacco Use Cessation Devices; Tobacco Use Disorder; Treatment Outcome; Varenicline	2016
Varenicline for smoking cessation and reduction in people with severe mental illnesses: systematic review and meta-analysis. Addiction (Abingdon, England), 2016, Volume: 111, Issue:9 Topics: Comorbidity; Humans; Mental Disorders; Nicotinic Agonists; Smoking; Smoking Cessation; Tobacco Smoking; Varenicline	2016
Clinical utility of varenicline for smokers with medical and psychiatric comorbidity. International journal of chronic obstructive pulmonary disease, 2009, Volume: 4 Topics: Benzazepines; Cardiovascular Diseases; Drug Labeling; Humans; Mental Disorders; Nicotinic Agonists; Pulmonary Disease, Chronic Obstructive; Quinoxalines; Smoking; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome; Varenicline	2009
Varenicline use in patients with mental illness: an update of the evidence. Expert opinion on drug safety, 2010, Volume: 9, Issue:3 Topics: Benzazepines; Evidence-Based Medicine; Humans; Limbic System; Mental Disorders; Mood Disorders; Patient Education as Topic; Quinoxalines; Smoking; Smoking Cessation; Suicide; Treatment Outcome; Varenicline	2010
Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis. Drug safety, 2010, Apr-01, Volume: 33, Issue:4 Topics: Adolescent; Adult; Aged; Benzazepines; Double-Blind Method; Female; Humans; Incidence; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Placebos; Quinoxalines; Randomized Controlled Trials as Topic; Risk; Sleep Wake Disorders; Smoking Cessation; Varenicline	2010
Neuropsychiatric adverse events of varenicline: a systematic review of published reports. Journal of clinical psychopharmacology, 2013, Volume: 33, Issue:1 Topics: Adult; Aged; Benzazepines; Comorbidity; Female; Humans; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Quinoxalines; Risk Assessment; Risk Factors; Smoking Cessation; Smoking Prevention; Time Factors; Varenicline; Young Adult	2013

Trials

8 trial(s) available for varenicline and Behavior Disorders

Article	Year
The effectiveness and safety of combining varenicline with nicotine e-cigarettes for smoking cessation in people with mental illnesses and addictions: study protocol for a randomised-controlled trial. BMC public health, 2018, 05-04, Volume: 18, Issue:1 Topics: Adult; Combined Modality Therapy; Electronic Nicotine Delivery Systems; Female; Humans; Male; Mental Disorders; Motivation; New Zealand; Smoking; Smoking Cessation; Substance-Related Disorders; Treatment Outcome; Varenicline	2018
Nicotine metabolite ratio and smoking outcomes using nicotine replacement therapy and varenicline among smokers with and without psychiatric illness. Journal of psychopharmacology (Oxford, England), 2018, Volume: 32, Issue:9 Topics: Female; Humans; Male; Mental Disorders; Middle Aged; Nicotine; Smoking; Smoking Cessation; Smoking Cessation Agents; Time Factors; Tobacco Use Cessation Devices; Treatment Outcome; Varenicline	2018
Predictors of Neuropsychiatric Adverse Events with Smoking Cessation Medications in the Randomized Controlled EAGLES Trial. Journal of general internal medicine, 2019, Volume: 34, Issue:6 Topics: Adult; Bupropion; Cohort Studies; Double-Blind Method; Female; Humans; Internationality; Male; Mental Disorders; Middle Aged; Predictive Value of Tests; Prospective Studies; Smoking Cessation; Smoking Cessation Agents; Tobacco Smoking; Tobacco Use Cessation Devices; Varenicline	2019
Flexible and extended dosing of nicotine replacement therapy or varenicline in comparison to fixed dose nicotine replacement therapy for smoking cessation: rationale, methods and participant characteristics of the FLEX trial. Contemporary clinical trials, 2014, Volume: 38, Issue:2 Topics: Adult; Benzazepines; Female; Humans; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Quinoxalines; Research Design; Smoking Cessation; Socioeconomic Factors; Substance Withdrawal Syndrome; Tobacco Use Cessation Devices; Varenicline	2014
Expanding Cessation Pharmacotherapy Via Videoconference Educational Outreach to Prescribers. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2015, Volume: 17, Issue:8 Topics: Adult; Community Mental Health Services; Female; Humans; Male; Medicaid; Mental Disorders; Middle Aged; Prescriptions; Psychiatry; Smoking; Smoking Cessation; Tobacco Use Disorder; United States; Varenicline; Videoconferencing	2015
Weight gain and 10-year cardiovascular risk with sustained tobacco abstinence in smokers with serious mental illness: a subgroup analysis of a randomized trial. The Journal of clinical psychiatry, 2016, Volume: 77, Issue:3 Topics: Cardiovascular Diseases; Diabetes Mellitus; Female; Humans; Hypertension; Male; Mental Disorders; Middle Aged; Obesity; Remission Induction; Smoking Cessation; Varenicline; Weight Gain	2016
Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet (London, England), 2016, Jun-18, Volume: 387, Issue:10037 Topics: Adolescent; Adult; Aged; Bupropion; Dopamine Uptake Inhibitors; Double-Blind Method; Female; Humans; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Smoking; Smoking Cessation; Smoking Prevention; Tobacco Use Cessation Devices; Treatment Outcome; Varenicline; Young Adult	2016
Smoking outcome by psychiatric history after behavioral and varenicline treatment. Journal of substance abuse treatment, 2010, Volume: 38, Issue:4 Topics: Adult; Behavior Therapy; Benzazepines; Combined Modality Therapy; Directive Counseling; Female; Follow-Up Studies; Humans; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Treatment Outcome; Varenicline	2010

Other Studies

40 other study(ies) available for varenicline and Behavior Disorders

Article	Year
Insights Into Improving Clinical Outcomes Across Psychiatric Disorders and Medical Comorbidities. The American journal of psychiatry, 2021, 09-01, Volume: 178, Issue:9 Topics: Alcoholism; Anorexia Nervosa; Attention Deficit Disorder with Hyperactivity; Comorbidity; Humans; Mental Disorders; Methadone; Naltrexone; Narcotics; Patient Outcome Assessment; Schizophrenia; Smoking; Varenicline	2021
Varenicline and Nicotine Replacement Use Associated With US Food and Drug Administration Drug Safety Communications. JAMA network open, 2019, 09-04, Volume: 2, Issue:9 Topics: Epidemiologic Studies; Humans; Interrupted Time Series Analysis; Medicaid; Mental Disorders; Nicotinic Agonists; United States; United States Food and Drug Administration; Varenicline	2019
Cardiovascular and neuropsychiatric safety of smoking cessation pharmacotherapies in non-depressed adults: a retrospective cohort study. Addiction (Abingdon, England), 2020, Volume: 115, Issue:8 Topics: Adolescent; Adult; Aged; Bupropion; Cardiovascular Diseases; Cohort Studies; Female; Humans; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Retrospective Studies; Smoking Cessation; Smoking Cessation Agents; Tobacco Use Cessation Devices; Tobacco Use Disorder; United States; Varenicline; Young Adult	2020
Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease. Thorax, 2017, Volume: 72, Issue:10 Topics: Adult; Bupropion; Cardiovascular Diseases; Dopamine Uptake Inhibitors; England; Female; Humans; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Propensity Score; Pulmonary Disease, Chronic Obstructive; Retrospective Studies; Risk Factors; Smoking Cessation; Tobacco Use Cessation Devices; Varenicline	2017
Cardiovascular and Neuropsychiatric Events after Varenicline Use for Smoking Cessation. American journal of respiratory and critical care medicine, 2018, 04-01, Volume: 197, Issue:7 Topics: Aged; Cardiovascular Diseases; Emergency Service, Hospital; Female; Hospitalization; Humans; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Ontario; Smoking Cessation; Varenicline	2018
Prescribing Prevalence, Effectiveness, and Mental Health Safety of Smoking Cessation Medicines in Patients With Mental Disorders. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2020, 01-27, Volume: 22, Issue:1 Topics: Drug Prescriptions; Female; Humans; Male; Mental Disorders; Mental Health; Middle Aged; Nicotine; Nicotinic Agonists; Prospective Studies; Smoking Cessation; Tobacco Use Cessation Devices; Tobacco Use Disorder; Varenicline	2020
Use of varenicline versus bupropion and risk of psychiatric adverse events. Addiction (Abingdon, England), 2013, Volume: 108, Issue:7 Topics: Adult; Benzazepines; Bupropion; Denmark; Dopamine Uptake Inhibitors; Female; Humans; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Proportional Hazards Models; Quinoxalines; Risk Factors; Smoking Cessation; Smoking Prevention; Treatment Outcome; Varenicline	2013
Neuropsychiatric events with varenicline: a modified prescription-event monitoring study in general practice in England. Drug safety, 2013, Volume: 36, Issue:7 Topics: Adult; Adverse Drug Reaction Reporting Systems; Benzazepines; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; England; Female; General Practice; Humans; Incidence; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Product Surveillance, Postmarketing; Quinoxalines; Smoking Cessation; Varenicline	2013
Varenicline, smoking cessation, and neuropsychiatric adverse events. The American journal of psychiatry, 2013, Volume: 170, Issue:12 Topics: Adult; Aggression; Akathisia, Drug-Induced; Benzazepines; Bupropion; Depression; Female; Humans; Male; Mental Disorders; Nausea; Observational Studies as Topic; Psychomotor Agitation; Quinoxalines; Randomized Controlled Trials as Topic; Risk Factors; Smoking Cessation; Suicidal Ideation; Suicide, Attempted; Tobacco Use Cessation Devices; Treatment Outcome; Varenicline	2013
[Abstinence rates among varenicline are highest]. Medizinische Monatsschrift fur Pharmazeuten, 2014, Volume: 37, Issue:5 Topics: Benzazepines; Bupropion; Humans; Mental Disorders; Quinoxalines; Smoking Cessation; Treatment Outcome; Varenicline	2014
Mental health effects of varenicline. BMJ (Clinical research ed.), 2015, Mar-17, Volume: 350 Topics: Benzazepines; Humans; Mental Disorders; Quinoxalines; Sleep Wake Disorders; Tobacco Use Cessation Devices; Varenicline	2015
Varenicline and risk of psychiatric conditions, suicidal behaviour, criminal offending, and transport accidents and offences: population based cohort study. BMJ (Clinical research ed.), 2015, Jun-02, Volume: 350 Topics: Accidents, Traffic; Adolescent; Adult; Aged; Benzazepines; Cohort Studies; Crime; Epidemiologic Methods; Female; Humans; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Smoking Prevention; Substance Withdrawal Syndrome; Suicide; Tobacco Use Cessation Devices; Varenicline; Young Adult	2015
Mental health status of varenicline and bupropion users during a quit attempt compared to current smokers, other quitters, and non-smokers. Drug and alcohol dependence, 2015, Sep-01, Volume: 154 Topics: Adolescent; Adult; Aged; Bupropion; Cross-Sectional Studies; Female; Humans; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Smoking; Smoking Cessation; United States; Varenicline; Young Adult	2015
Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study. The Lancet. Respiratory medicine, 2015, Volume: 3, Issue:10 Topics: Adult; Bupropion; Cardiovascular Diseases; Depression; Dopamine Uptake Inhibitors; Female; Humans; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Retrospective Studies; Smoking Cessation; Tobacco Use Cessation Devices; Varenicline	2015
Reframing the varenicline question: have anecdotes and emotional filters clouded our decision making? The Lancet. Respiratory medicine, 2015, Volume: 3, Issue:10 Topics: Cardiovascular Diseases; Female; Humans; Male; Mental Disorders; Nicotinic Agonists; Tobacco Use Cessation Devices; Varenicline	2015
Cardiovascular and neuropsychiatric risks of varenicline: too good to be true? The Lancet. Respiratory medicine, 2015, Volume: 3, Issue:12 Topics: Cardiovascular Diseases; Female; Humans; Male; Mental Disorders; Nicotinic Agonists; Tobacco Use Cessation Devices; Varenicline	2015
Cardiovascular and neuropsychiatric risks of varenicline: too good to be true? The Lancet. Respiratory medicine, 2015, Volume: 3, Issue:12 Topics: Cardiovascular Diseases; Female; Humans; Male; Mental Disorders; Nicotinic Agonists; Tobacco Use Cessation Devices; Varenicline	2015
Cardiovascular and neuropsychiatric risks of varenicline: too good to be true? - Authors' reply. The Lancet. Respiratory medicine, 2015, Volume: 3, Issue:12 Topics: Cardiovascular Diseases; Female; Humans; Male; Mental Disorders; Nicotinic Agonists; Tobacco Use Cessation Devices; Varenicline	2015
Cardiovascular and neuropsychiatric risks of varenicline: too good to be true? The Lancet. Respiratory medicine, 2015, Volume: 3, Issue:12 Topics: Cardiovascular Diseases; Female; Humans; Male; Mental Disorders; Nicotinic Agonists; Tobacco Use Cessation Devices; Varenicline	2015
A comparison of neuropsychiatric adverse events during early treatment with varenicline or a nicotine patch. Addiction (Abingdon, England), 2016, Volume: 111, Issue:7 Topics: Adult; Aged; Ambulatory Care; Cohort Studies; Drug Labeling; Female; Hospitalization; Humans; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Propensity Score; Proportional Hazards Models; Retrospective Studies; Tobacco Smoking; Tobacco Use Cessation Devices; United States; United States Department of Veterans Affairs; Varenicline	2016
Cardiovascular and neuropsychiatric risks of varenicline - Authors' reply. The Lancet. Respiratory medicine, 2016, Volume: 4, Issue:3 Topics: Cardiovascular Diseases; Female; Humans; Male; Mental Disorders; Nicotinic Agonists; Tobacco Use Cessation Devices; Varenicline	2016
Cardiovascular and neuropsychiatric risks of varenicline. The Lancet. Respiratory medicine, 2016, Volume: 4, Issue:3 Topics: Cardiovascular Diseases; Female; Humans; Male; Mental Disorders; Nicotinic Agonists; Tobacco Use Cessation Devices; Varenicline	2016
Safety of Varenicline for Smoking Cessation in Psychiatric and Addicts Patients. Substance use & misuse, 2016, Volume: 51, Issue:5 Topics: Adult; Counseling; Female; Humans; Longitudinal Studies; Male; Mental Disorders; Middle Aged; Prospective Studies; Smoking; Smoking Cessation; Substance-Related Disorders; Tobacco Use Cessation Devices; Varenicline	2016
Varenicline (Chantix) warnings: risk versus benefit. The Medical letter on drugs and therapeutics, 2008, Jul-14, Volume: 50, Issue:1290 Topics: Benzazepines; Drug Partial Agonism; Humans; Mental Disorders; Nicotinic Agonists; Quinoxalines; Risk Assessment; Risk Factors; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome; Varenicline	2008
Neuropsychiatric disturbance after initiation of varenicline in a patient with a history of alcohol abuse and major depression. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008, Sep-01, Volume: 65, Issue:17 Topics: Adult; Alcoholism; Benzazepines; Depressive Disorder, Major; Humans; Male; Mental Disorders; Nervous System Diseases; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Tobacco Use Disorder; Varenicline	2008
Varenicline and smokers with mental illnesses. Lancet (London, England), 2008, Oct-04, Volume: 372, Issue:9645 Topics: Benzazepines; Humans; Mental Disorders; Patient Selection; Quinoxalines; Randomized Controlled Trials as Topic; Risk Factors; Smoking Cessation; Varenicline	2008
Varenicline for tobacco dependence. The New England journal of medicine, 2009, Feb-12, Volume: 360, Issue:7 Topics: Benzazepines; Humans; Mental Disorders; Nicotinic Agonists; Quinoxalines; Smoking; Suicide; Tobacco Use Disorder; Varenicline	2009
Safety and effectiveness of varenicline in a veteran population with a high prevalence of mental illness. The Annals of pharmacotherapy, 2009, Volume: 43, Issue:5 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Benzazepines; Diagnosis, Dual (Psychiatry); Female; Humans; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Quinoxalines; Retrospective Studies; Sex Factors; Smoking Cessation; Tobacco Use Disorder; Varenicline; Veterans	2009
[Tolerability profile of varenicline in current medical practice]. Presse medicale (Paris, France : 1983), 2010, Volume: 39, Issue:1 Topics: Adult; Benzazepines; Female; France; Gastrointestinal Diseases; Humans; Male; Mental Disorders; Metabolic Diseases; Nervous System Diseases; Nicotinic Agonists; Quinoxalines; Retrospective Studies; Skin Diseases; Smoking; Varenicline	2010
A retrospective poison center review of varenicline-exposed patients. The Annals of pharmacotherapy, 2009, Volume: 43, Issue:12 Topics: Adolescent; Adult; Benzazepines; Child, Preschool; Databases, Factual; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Infant; Male; Medication Errors; Mental Disorders; Nicotinic Agonists; Poison Control Centers; Quinoxalines; Retrospective Studies; Smoking Cessation; Varenicline	2009
Regulation of smoking cessation drugs by the Food and Drug Administration. Food and drug law journal, 2009, Volume: 64, Issue:2 Topics: Benzazepines; Clinical Trials as Topic; Drug Approval; Drug Interactions; Government Regulation; Humans; Mental Disorders; Nicotinic Agonists; Product Surveillance, Postmarketing; Psychotropic Drugs; Quinoxalines; Smoking; Smoking Cessation; United States; United States Food and Drug Administration; Varenicline	2009
Thoughts and acts of aggression/violence toward others reported in association with varenicline. The Annals of pharmacotherapy, 2010, Volume: 44, Issue:9 Topics: Adult; Aggression; Benzazepines; Female; Humans; Male; Mental Disorders; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Thinking; Varenicline; Violence	2010
Psychiatric adverse events associated with varenicline: an intensive postmarketing prospective cohort study in New Zealand. Drug safety, 2011, Sep-01, Volume: 34, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Benzazepines; Cohort Studies; Female; Follow-Up Studies; Humans; Male; Mental Disorders; Middle Aged; New Zealand; Nicotinic Agonists; Product Surveillance, Postmarketing; Prospective Studies; Quinoxalines; Sleep Wake Disorders; Smoking Cessation; Surveys and Questionnaires; Varenicline; Young Adult	2011
Treatment of nicotine dependence with Chantix (varenicline). Texas dental journal, 2011, Volume: 128, Issue:5 Topics: Adult; Benzazepines; Disclosure; Drug Interactions; Humans; Mental Disorders; Nausea; Nicotinic Agonists; Product Surveillance, Postmarketing; Quinoxalines; Randomized Controlled Trials as Topic; Risk Assessment; Safety; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome; Varenicline; Young Adult	2011
Neuropsychiatric events in varenicline and nicotine replacement patch users in the Military Health System. Addiction (Abingdon, England), 2013, Volume: 108, Issue:1 Topics: Adult; Aged; Benzazepines; Bupropion; Female; Hospitalization; Humans; Male; Mental Disorders; Middle Aged; Military Personnel; Nicotinic Agonists; Quinoxalines; Retrospective Studies; Smoking Cessation; Tobacco Use Cessation Devices; United States; Varenicline; Young Adult	2013
Low incidence of adverse events following varenicline initiation among opioid dependent smokers with comorbid psychiatric illness. Drug and alcohol dependence, 2013, Sep-01, Volume: 132, Issue:1-2 Topics: Benzazepines; Cardiovascular Diseases; Comorbidity; Data Interpretation, Statistical; Female; Humans; Longitudinal Studies; Male; Mental Disorders; Methadone; Middle Aged; Narcotics; Nicotinic Agonists; Opioid-Related Disorders; Prevalence; Primary Health Care; Quinoxalines; Smoking; Smoking Cessation; Socioeconomic Factors; Treatment Outcome; Varenicline	2013
Efficacy of varenicline for smoking cessation. JAMA, 2006, Dec-06, Volume: 296, Issue:21 Topics: Benzazepines; Humans; Mental Disorders; Quinoxalines; Smoking; Smoking Cessation; Varenicline	2006
Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction (Abingdon, England), 2008, Volume: 103, Issue:1 Topics: Adult; Benzazepines; Cohort Studies; Drug Combinations; Female; Follow-Up Studies; Humans; London; Male; Mental Disorders; Middle Aged; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Disorder; Treatment Outcome; Varenicline	2008
FDA warns of adverse events linked to smoking cessation drug and antiepileptics. JAMA, 2008, Mar-12, Volume: 299, Issue:10 Topics: Anticonvulsants; Benzazepines; Humans; Mental Disorders; Quinoxalines; Risk; Smoking Cessation; Suicide; United States; United States Food and Drug Administration; Varenicline	2008
Empowering dental hygienists: tobacco cessation resources. International journal of dental hygiene, 2008, Volume: 6, Issue:2 Topics: Benzazepines; Dental Hygienists; Humans; Mental Disorders; Nicotinic Agonists; Product Surveillance, Postmarketing; Quinoxalines; Smoking Cessation; United States; United States Food and Drug Administration; Varenicline	2008